Early Immune Dysregulation Emerges During the Advanced Adenoma–Carcinoma Transition Through PD-1/PD-L1 Checkpoint Remodeling

The human body maintains a delicate balance between its immune system and its own tissues. The immune system acts as a vigilant defense force, constantly patrolling to identify and destroy abnormal cells before they can cause harm. However, to prevent this defense force from attacking healthy tissue by mistake, the body uses a series of "brakes" known as immune checkpoints. These checkpoints are like safety switches on a machine; they tell immune cells to stand down when they encounter normal cells. One of the most important of these switches involves two proteins: PD-1, which sits on the surface of immune cells, and PD-L1, which is found on many other cells in the body. When these two proteins meet, they send a signal to the immune cell to stop its attack. This system is vital for health, but it can be hijacked by cancer. Tumors often learn to display high levels of PD-L1 to trick the immune system into thinking the cancer is a harmless part of the body, effectively turning off the immune response and allowing the disease to grow unchecked.

Understanding how this hijacking begins is crucial for catching cancer early. Colorectal cancer, which starts in the lining of the colon, typically develops slowly over many years. It often begins as a small, benign growth called an adenoma, which can eventually transform into a dangerous, invasive tumor. Scientists have long known that the immune system plays a role in this process, but the exact moment when the immune brakes begin to fail has remained unclear. Researchers in Iran set out to investigate this transition, looking specifically at how the genes controlling these immune checkpoints change as a healthy colon lining turns into a polyp and then into cancer. By studying tissue samples from healthy individuals, those with advanced polyps, and those with confirmed cancer, they aimed to see if the body's immune regulation breaks down at the very earliest stages of the disease.

The researchers examined tissue samples from three distinct groups: people with healthy colon linings, patients with advanced adenomas (large or high-risk polyps), and patients with colorectal cancer. They focused on two specific genes, one that produces the PD-1 protein and another that produces the PD-L1 protein. To understand how these genes were behaving, the team looked at two things: how much of the protein was being made (gene expression) and how the genes were chemically tagged (DNA methylation). These chemical tags act like volume knobs or locks on a gene; adding them can silence a gene, while removing them can allow it to become active. The team compared the cancerous tissue and the polyps against the healthy tissue from the same patients to see how the immune landscape shifted as the disease progressed.

The study revealed a clear and progressive shift in how these immune checkpoints were regulated. As the tissue moved from a healthy state to a polyp and finally to cancer, the amount of PD-1 protein made by immune cells steadily decreased. This drop was significant, suggesting that the immune cells were losing their ability to signal or respond effectively as the disease advanced. In contrast, the production of PD-L1, the protein that acts as the "off switch," increased dramatically, reaching its highest levels in the cancerous tissue. This pattern indicates that as the tumor grows, it becomes increasingly aggressive in trying to shut down the immune system.

A key discovery was that this change in PD-L1 production was linked to the removal of chemical tags on the gene itself. In the early stages of polyp formation, the researchers found that the DNA tags that usually keep the PD-L1 gene in check were disappearing. This loss of tags, known as hypomethylation, effectively unlocked the gene, allowing it to produce more of the PD-L1 protein. This suggests that the cancer cells begin to reprogram their own immune defenses very early in the disease process, long before the tumor becomes invasive. Interestingly, the researchers found that this early increase in PD-L1 was particularly strong in women with polyps, who showed significantly higher levels of the protein compared to men with similar polyps. This points to a sex-specific difference in how the immune system is regulated during the earliest phases of colorectal neoplasia.

The study also looked at how these changes related to the presence of immune cells within the tissue. In the polyp stage, the researchers observed a specific connection between the chemical tags on the PD-1 gene and the density of immune cells infiltrating the tissue. This suggests that the local environment of the polyp is actively shaping the genetic regulation of the immune system. However, as the disease progressed to cancer, the relationship between the amount of protein made and the number of immune cells present became less direct, indicating that the tumor was developing more complex ways to control its immune environment.

Perhaps most importantly, the researchers found that the coordinated relationship between the PD-1 and PD-L1 genes, which exists in healthy tissue, began to break down as the disease progressed. In healthy colon lining, these two genes worked in a synchronized manner, maintaining a stable immune balance. In the polyps and cancer tissues, this coordination was lost, and the genes began to behave independently. This uncoupling suggests that the precise control the body exerts over its immune system is one of the first things to fail during the transition from a benign polyp to a malignant tumor.

The findings offer a new perspective on how colorectal cancer develops. Rather than a sudden event, the immune system's failure appears to be a gradual process that begins with specific genetic and chemical changes in the earliest precancerous lesions. The fact that these changes occur in polyps, which are often removed during routine screening, highlights the potential for early intervention. By identifying these early shifts in immune regulation, particularly the sex-specific differences and the loss of chemical tags on the PD-L1 gene, scientists may be able to develop better tools for predicting which polyps are likely to become dangerous. The study confirms that the battle against colorectal cancer is not just about the growth of the tumor itself, but also about the subtle, early ways the tumor learns to hide from the body's own defenses.